CapeOx
2 clinical trials
1 product
6 abstracts
6 indications
Indication
ImmunotherapyIndication
Stomach CancerIndication
Rectal CancerIndication
Chemotherapy EffectIndication
RadiotherapyIndication
Colon CancerAbstract
Adjuvant chemotherapy in clinical local advanced CRC following preoperational therapies and pT0-3N0M0 diagnosis (CANWATCH).Org: Kunming, China,
Abstract
MIRACLE1: Phase II study of radiotherapy followed by CapeOx and tirelizumab as first-line treatment in MSS rectal cancer with synchronous resectable liver/lung metastases.Org: Department of Cancer Prevention,
Abstract
First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).Org: National Cancer Center Hospital East, Kashiwa, Japan, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan,
Abstract
Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.Org: Key Laboratory of Cancer Prevention and Intervention, Zhejiang University College of Medicine, Colorectal Surgery and Oncology,
Abstract
Phase II study of neoadjuvant short-course radiotherapy combined with CAPEOX plus envafolimab in patients with microsatellite stable locally advanced rectal cancer: Updated results of PRECAM study.Org: Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou Shengting Medical Technology Co., Ltd, Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences,
Clinical trial
Clinical Application of Efficacy Prediction Model Based on Epigenetics Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Single Arm Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Locally Advanced Colon CancersStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Abstract
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy.Org: Cancer Center Zhejiang University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,
Product
FOLFOX